Subsequent analyses of survival identified high-expression CD93 as a distinct prognostic variable for patients with gliomas, while earlier reports have displayed similar findings in the context of HGG (Langenkamp et al. 2015), nasopharyngeal carcinoma (Bao et al. 2016) and colon cancer (Olsen et al. 2015) but not in overall gliomas. This evidence concerns the gene CD93 and glioma.